The Glutamatergic System and Alzheimer's Disease: Therapeutic Implications

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2003 Jun 28

PMID 12828500

Citations 81

Authors

D Allan Butterfield

Chava B Pocernich

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzheimer's disease is a gradual loss of cognitive function. Glutamatergic neurotransmission, an important process in learning and memory, is severely disrupted in patients with Alzheimer's disease. Loss of glutamatergic function in Alzheimer's disease may be related to the increase in oxidative stress associated with the amyloid beta-peptide that is found in the brains of individuals who have the disease. Therefore, therapeutic strategies directed at the glutamatergic system may hold promise. Therapies addressing oxidative stress induced by hyperactivity of glutamate receptors include supplementation with estrogen and antioxidants such as tocopherol (vitamin E) and acetylcysteine (N-acetylcysteine). Therapy for hypoactivity of glutamate receptors is aimed at inducing the NMDA receptor with glycine and cycloserine (D-cycloserine). Recently, memantine, an NMDA receptor antagonist that addresses the hyperactivity of these receptors, has been approved in some countries for use in Alzheimer's disease.

Citing Articles

Drugs repurposing in the experimental models of Alzheimer's disease.

Joodi S, Ibrahim W, Khattab M Inflammopharmacology. 2025; 33(1):195-214.

PMID: 39752040 PMC: 11799062. DOI: 10.1007/s10787-024-01608-7.

Studies and Antioxidant and Neuroprotective Assessment of Microencapsulated Celecoxib against Scopolamine-induced Alzheimer's Disease.

Vishnumurthy R, Priya M, Tiwari P, Solomon V Curr Pharm Des. 2024; 31(4):320-329.

PMID: 39206485 DOI: 10.2174/0113816128298289240723103828.

Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer's Disease.

Flieger J, Forma A, Flieger W, Flieger M, Gawlik P, Dzierzynski E Int J Mol Sci. 2024; 25(16).

PMID: 39201668 PMC: 11354426. DOI: 10.3390/ijms25168982.

Acute and chronic excitotoxicity in ischemic stroke and late-onset Alzheimer's disease.

Yu S, Choi E, Jiang M, Wei L Neural Regen Res. 2024; 20(7):1981-1988.

PMID: 39101641 PMC: 11691467. DOI: 10.4103/NRR.NRR-D-24-00398.

How Do Retinoids Affect Alzheimer's Disease and Can They Be Novel Drug Candidates?.

Alsharief M Cureus. 2024; 16(4):e57548.

PMID: 38572181 PMC: 10990449. DOI: 10.7759/cureus.57548.

References

Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L . Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol. 1996; 40(5):759-66. DOI: 10.1002/ana.410400512. View

Hertz L, Drejer J, Schousboe A . Energy metabolism in glutamatergic neurons, GABAergic neurons and astrocytes in primary cultures. Neurochem Res. 1988; 13(7):605-10. DOI: 10.1007/BF00973275. View

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

Jain K . Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs. 2000; 9(6):1397-406. DOI: 10.1517/13543784.9.6.1397. View

Gandolfi O, Bonfante V, Voltattorni M, DallOlio R, Poli A, Pietra C . Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. Pharmacol Biochem Behav. 2001; 70(1):157-66. DOI: 10.1016/s0091-3057(01)00591-3. View

Sims K, Robinson M . Expression patterns and regulation of glutamate transporters in the developing and adult nervous system. Crit Rev Neurobiol. 1999; 13(2):169-97. DOI: 10.1615/critrevneurobiol.v13.i2.30. View

Chessell I, Procter A, Francis P, Bowen D . D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res. 1991; 565(2):345-8. DOI: 10.1016/0006-8993(91)91668-q. View

Butterfield D, Lauderback C . Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002; 32(11):1050-60. DOI: 10.1016/s0891-5849(02)00794-3. View

Howlett D, Jennings K, Lee D, Clark M, Brown F, Wetzel R . Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 1995; 4(1):23-32. DOI: 10.1006/neur.1995.0003. View

10.

Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C . Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995; 373(6514):523-7. DOI: 10.1038/373523a0. View

11.

Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein J, Pierce W . Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002; 33(4):562-71. DOI: 10.1016/s0891-5849(02)00914-0. View

12.

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S . Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 274(5284):99-102. DOI: 10.1126/science.274.5284.99. View

13.

Shimada A, Spangler E, London E, Ingram D . Spermidine potentiates dizocilpine-induced impairment of learning performance by rats in a 14-unit T-maze. Eur J Pharmacol. 1994; 263(3):293-300. DOI: 10.1016/0014-2999(94)90725-0. View

14.

Antuono P, Jones J, Wang Y, Li S . Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology. 2001; 56(6):737-42. DOI: 10.1212/wnl.56.6.737. View

15.

Gmiro V, Serdiuk S . [Bis-ammonium adamantane derivatives--novel modulators of polyamine binding sites]. Eksp Klin Farmakol. 2000; 63(3):16-20. View

16.

Butterfield D, Drake J, Pocernich C, Castegna A . Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 2001; 7(12):548-54. DOI: 10.1016/s1471-4914(01)02173-6. View

17.

Myhrer T . Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease. Neurosci Biobehav Rev. 1998; 23(1):131-9. DOI: 10.1016/s0149-7634(98)00039-6. View

18.

Davies C, Mann D, Sumpter P, YATES P . A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci. 1987; 78(2):151-64. DOI: 10.1016/0022-510x(87)90057-8. View

19.

Pocernich C, Cardin A, Racine C, Lauderback C, Butterfield D . Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int. 2001; 39(2):141-9. DOI: 10.1016/s0197-0186(01)00012-2. View

20.

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View